Research News
View articles by month and year
-
Number of Circulating Tumor Cells Affects Prognosis
New research suggests that knowing the actual number of circulating tumor cells in the blood may some day offer a better estimate of a cancer's prognosis.
-
Genetic Changes in DCIS Cells May Help Predict Invasive Breast Cancer Risk
New research suggests that certain genetic characteristics in DCIS cells may help predict the risk of future invasive breast cancer.
-
Diagnosed Women with Abnormal Breast Cancer Gene Have Higher Risk of New Cancer in Opposite Breast
Research suggests that women with an abnormal BRCA1 or BRCA2 gene who have been diagnosed with breast cancer are 4 times more likely to be diagnosed with a new cancer in the opposite breast compared to women without an abnormal breast cancer gene diagnosed with breast cancer.
-
Genomic Test Results Not Understood by Many Women
A small study found that about a third of women who had genomic testing didn't really understand the test results.
-
Aspirin Seems to Improve Prognosis
Research suggests that premenopausal women who took two or more aspirin each week in the years after a diagnosis of early-stage breast cancer have a better prognosis than women who don't take aspirin.
-
Breast Cancer Diagnosis and Death Rates Continue to Decline
The new Cancer Report Card shows that the decade-long decline in U.S. diagnosis and death rates from breast, colon, and ovarian cancer in women continues.
-
Breast Ultrasound May Help Younger Women Avoid Biopsies
Two studies strongly suggest that breast ultrasound is very good at distinguishing between benign lumps and cancer in women younger than 40 and may help some women avoid unnecessary biopsies.
-
Adding Special Analysis to Breast Ultrasound Might Help Decide if Mass Is Cancerous
A small study suggests that adding a special analysis -- called elastography -- to breast ultrasound can help doctors decide if a breast mass is cancer and needs to be biopsied.
-
Even Small HER2-Positive Cancers Have Higher Recurrence Risk
Small (1 cm or smaller), early-stage, HER2-positive breast cancers are more likely to come back (recur) and spread to parts of the body away from the breast (metastasize) than small, early-stage HER2-negative breast cancers, which suggests that treating these cancers with Herceptin (chemical name: trastuzumab) may make sense.
-
Breast Cancer Diagnosed Earlier in Families with Abnormal Gene
The age at which breast cancer is being diagnosed in families with an abnormal breast cancer gene seems to be getting younger, according to a new study.
